Study of the Disease Process of Lymphangioleiomyomatosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001465|
Recruitment Status : Recruiting
First Posted : November 4, 1999
Last Update Posted : November 4, 2022
Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor.
This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy.
Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.
|Condition or disease|
|Lung Disease Pneumothorax Tuberous Sclerosis Lymphangioleiomyomatosis|
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)|
|Actual Study Start Date :||December 18, 1995|
Patients with tissue diagnosis of LAM may be admitted for evaluation every six months, or as deemed necessary for research
- Define the clinical course of the disease LAM andelucidate the pathogenesis of LAM at cellular and molecular levels [ Time Frame: on going ]To define the molecular basis of the remarkable proliferation of immature appearing smooth muscle cells, which is the cause of many of the clinical manifestations, and perhaps thereby to improve our understanding of the mechanism of smooth muscle cell proliferation in other diseases, e.g., interstitial lung diseases, asthma, atherosclerosis, hypertension, and post-angioplastic coronary restenosis. To assess the contribution of proteins and genetic factors to cyst formation, airway obstruction, and clinical course. To evaluate the role of TSC genes in the pathogenesis of LAM.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001465
|Contact: Tatyana Worthy, R.N.||(301) email@example.com|
|Contact: Joel Moss, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Joel Moss, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|